Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) remains negative
Q1 FY2026 property, plant & equipment (net) was $0, compared with $0 a year earlier.
Context
- Property, plant & equipment (net) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Property, plant & equipment (net) amounts to 0.0% of total assets for GLSI, versus a peer median of 4.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $33.38M USD | -15.0% | -8.8% | 12.3% | |
| Mar 2026 | $22.41M USD | -84.4% | -47.2% | 12.0% | |
| Mar 2026 | $6.04M USD | -21.0% | -2.3% | 5.0% | |
| Mar 2026 | $3.36M USD | +8.5% | +893.3% | 3.5% | |
| Mar 2026 | $675.65K USD | +115.7% | +17.9% | 2.3% | |
| Mar 2026 | CA$674K CAD | -44.5% | +15.8% | 8.3% | |
| Mar 2026 | $326K USD | -48.6% | -27.5% | 0.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $186K USD | -22.2% | +221.3% | 0.3% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding GLSI) | — | -21.6% | +6.8% | 4.3% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.